Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CelcuityFRA:7VR 18 Debt-to-Equity is 6.04 as of Mar. 2026, which is 2137% above its 10-year median of 0.27. GuruFocus rates FRA:7VR with a GF Score™ of 18/100. The stock has 2 warning signs investors should review. Among 966 Biotechnology companies, Celcuity ranks worse than 98.24% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Celcuity's Debt-to-Equity or its related term are showing as below:
FRA:7VR'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.27 Max: 6.04
Current: 6.04
During the past 11 years, the highest Debt-to-Equity Ratio of Celcuity was 6.04. The lowest was 0.00. And the median was 0.27.
FRA:7VR's Debt-to-Equity is ranked worse than 98.24% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:7VR: 6.04
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Celcuity Debt-to-Equity Related Terms
Celcuity Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Celcuity's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7VR vs RLAY, VKTX, DYN: Debt-to-Equity Comparison
For the Biotechnology subindustry, Celcuity's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celcuity Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celcuity's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Celcuity's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celcuity (FRA:7VR) has a Debt-to-Equity of 6.04 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Celcuity and its competitors. This is 2137% above median its historical median of 0.27. According to the industry distribution chart, Celcuity ranks #949 out of 966 companies in the Biotechnology industry, placing it in the top 98.2%.
Is Celcuity's Debt-to-Equity too high?
Celcuity's current Debt-to-Equity of 6.04 is 2137% above median its 10-year median of 0.27. The Biotechnology industry median Debt-to-Equity is 0.16. Celcuity's value of 6.04 is 3675% above this industry median. Based on the distribution chart, Celcuity ranks #949 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Celcuity has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Celcuity's Debt-to-Equity compare to RLAY and VKTX?
According to the Biotechnology industry distribution chart, Celcuity ranks #949 out of 966 companies for Debt-to-Equity. This places Celcuity in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Celcuity's value of 6.04 is 3675% above this benchmark. While the company's 10-year median is 0.27 vs. the industry median of 0.16, Celcuity has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celcuity's current Debt-to-Equity of 6.04 is 3675% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Celcuity and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celcuity's current Debt-to-Equity is 6.04, which is 2137% above median its own 10-year median of 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celcuity stock overvalued right now?
Celcuity (FRA:7VR) has a current Debt-to-Equity of 6.04. The current Debt-to-Equity is 6.04, which is 2137% above median its 10-year median of 0.27 and 3675% above the Biotechnology industry median of 0.16. Celcuity's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Celcuity (FRA:7VR), the current Debt-to-Equity is 6.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
18GF Score
Get the complete analysis for FRA:7VR
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7VR has been successfully added to your 
